Lineage Cell Therapeutics unveils plans to ink three new license deals
Category: #health  By Mateen Dalal  Date: 2019-12-26
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Lineage Cell Therapeutics unveils plans to ink three new license deals

Lineage Cell Therapeutics, a California based clinical stage biotechnology company, that develops novel cellular therapies for medical needs that are not fulfilled, has reportedly announced its plans to enter into license deals with three different companies, each of which are different parts of intellectual property portfolio of Lineage.

The three companies have currently ongoing commercial operations with respect to their related assets of cell therapy. The accumulated upfront cash payment made from the transactions was more than $1 million along with additional royalties and cash that were due upon arriving at certain milestones or product sales.

Brian M. Culley, CEO, Lineage Cell Therapeutics, reportedly stated that the company is a renowned cell-based therapy platform with a technology that is clinically validated which is based on one of the most comprehensive and largest patent estates in cell therapy. The company believes that their IP estate increased due to advancements made by them and others involved in the field of cell therapy.

Culley, further added that they have put a greater emphasis on completing their transactions of business development that will help in funding their operations without the need to raise capitals at prices that are unattractive.  The company entered into three different agreements with establishment in the cell therapy space for the development, license, manufacture and lastly sale of products based on the company’s technologies and their broad cell therapy platform.

The new agreements are with companies that have already commercialized assets related to cell therapy and are well-positioned to take the company’s programs further. It is believed that these partnerships help in validating the superiority of the company’s human cell lines that are well-characterized and NIH-approved.

 

The company is also seeking external partnership opportunities so that it could support the development of their three cell therapy programs that are OPC1, VAC2 and OpRegen®, with each program representing market opportunities that are worth billion dollars in the emerging field of immuno-oncology and cell therapy.

 

Source credit: https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-enters-three-separate-license

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

Xiaomi and Oppo team up with UNISOC to manufacture in-house 5G chipsets

By Mateen Dalal

The two companies intend to introduce their custom-made sub-6GHz 5G chipsets by the end of 2021. UNISOC has managed to raise around USD 817.20 million for its new venture. Chinese electronics giants including Xiaomi Corp. and Guangdong Oppo Mob...

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

Twitter explored USD 4 billion takeover of audio-chat app Clubhouse

By Mateen Dalal

Twitter, an American microblogging service company, had touted plans of acquiring Clubhouse, an audio chat iPhone app and live drop-in audio networking platform. The deal was estimated to be valued at around USD 4 billion, as per reliable sources. T...

Beyond Meat sets up factory in China to expedite localized innovation

Beyond Meat sets up factory in China to expedite localized innovation

By Mateen Dalal

American plant-based meat substitute producer Beyond Meat has opened a new production facility in China. Apparently, this recent setup is the company’s first facility outside the U.S., making it the only multinational organization solely focusi...